CLINICAL APPLICATIONS OF GENOMIC DECODING IN PERSONALIZED PROACTIVE HEALTHCARE FOR CHRONIC NON-COMMUNICABLE DISEASES AND CANCER.

Dang Thi Thuy Duong1, Doan Van Khoi2, Ngo Thi Thao1, Pham Kim Tuyen3, Bui Thang Loi3, Ha Quoc Duong1, Tran Quang Huu1, Tang Thi Nga4, Tran Quang Canh1,5
1 Hai Duong Medical Technical University
2 VP Med Tan Hung Hospital
3 Hai Duong University
4 National Institute of Hygiene and Epidemiology
5 Hai Phong Department of Health

Main Article Content

Abstract

Objective: To synthesize recent research on the role of genetics in chronic non-communicable diseases, with a particular focus on the nutrigenomics approach as a key strategy for proactive healthcare and effective prevention of prevalent conditions such as diabetes, cardiovascular disease, stroke, and cancer. Methods: A literature synthesis was conducted, analyzing recent research advancements in genetic testing, nutrigenomics, and their application in proactive healthcare. The study emphasizes findings relevant to the Vietnamese context, where implementation remains limited. Results: Advances in Next-Generation Sequencing and Artificial Intelligence have significantly reduced sequencing time and costs, enabling comprehensive genetic risk screening and lifestyle modification strategies. While these approaches are widely applied in developed nations, their utilization in Vietnam is still in its early stages. Key findings demonstrate the potential of nutrigenomics in assessing genetic predispositions and guiding personalized interventions for chronic diseases. Conclusion: Genomic decoding and nutrigenomics offer promising avenues for proactive and personalized healthcare in Vietnam. Addressing current challenges, including limited clinical implementation and population-specific genetic data, could facilitate the integration of genetic information into disease prevention strategies, ultimately improving health outcomes for chronic non-communicable diseases.

Article Details

References

[1] World Health Organization. Noncommunicable diseases (NCDs) fact sheet [Internet]. Geneva: World Health Organization; 2024 [cited 2026 Feb 7]. Available from: https://www.who.int/news-room/fact-sheets/detail/noncommunicable-diseases.
[2] World Health Organization. Cardiovascular diseases [Internet]. Geneva: World Health Organization; 2024 [cited 2026 Feb 7]. Available from: https://www.who.int/vietnam/health-topics/cardiovascular-diseases/cardiovascular-diseases.
[3] Chowns J, Patel RS, Thanassoulis G, et al. Cardiovascular genetics: the role of genetics in predicting risk. Med Clin North Am. 2022;106(2):313–324. doi:10.1016/j.mcna.2021.11.007.
[4] Hachiya T, Kubo M, Hirakawa Y, et al. Genome-wide polygenic score and the risk of ischemic stroke in a prospective cohort: the Hisayama study. Stroke. 2020;51:759–765. doi:10.1161/STROKEAHA.119.027520.
[5] Wang M, Menon R, Mishra S, et al. Validation of a genome-wide polygenic score for coronary artery disease in South Asians. J Am Coll Cardiol. 2020;76:703–714. doi:10.1016/j.jacc.2020.06.024
[6] González-Quijano GK, Martínez-González MÁ, Fernández-Montero A, et al. Effect of genotype on the response to diet in cardiovascular disease: a scoping review. Healthcare (Basel). 2024;12:2292. doi:10.3390/healthcare12222292.
[7] Fallaize R, Carvalho-Wells AL, Tierney AC, et al. APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the metabolic syndrome. Sci Rep. 2017;7:6274. doi:10.1038/s41598-017-05802-2.
[8] Kushwaha S, Singh P, Gupta A, et al. An exploratory, open-label, parallel-group, randomised controlled trial evaluating the effect of gene-based nutritional intervention in type 2 diabetes: the protocol for NUDGE clinical trial. Contemp Clin Trials Commun. 2025;45:101470. doi:10.1016/j.conctc.2025.101470.
[9] Wang F, Li Y, Zhang Y, et al. Personalized nutrition: a review of genotype-based nutritional supplementation. Front Nutr. 2022;9:992986. doi:10.3389/fnut.2022.992986.
[10] Natarajan P, Young R, Stitziel NO, et al. Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation. 2017;135:2091–2101. doi:10.1161/CIRCULATIONAHA.116.024436.